OTCM
GNCAQ
Market cap0kUSD
Jun 02, Last price
0.00USD
Name
Genocea Biosciences Inc
Chart & performance
P/E
—
P/S
0.00
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
26.62%
Revenues
2m
+20.75%
Net income
-15m
L-64.73%
CFO
-45m
L+8.93%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Genocea Biosciences, Inc. is a biopharmaceutical company focused on pioneering novel cancer immunotherapies. It leverages its distinctive ATLAS discovery platform to meticulously profile each patient's CD4+ and CD8+ T cell immune responses against specific targets or antigens, which are identified through next-generation sequencing of their individual tumors. Among its lead clinical-stage candidates is GEN-011, an adoptive T cell therapy currently in Phase 1/2a trials for solid tumors. Also undergoing Phase 1/2a clinical evaluation is GEN-009, an investigational neoantigen vaccine designed to deliver adjuvanted synthetic long peptides corresponding to anti-tumor neoantigens pinpointed by ATLAS. Established in 2006 and based in Cambridge, Massachusetts, the company notably filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts on July 5, 2022.
Key people
Independent Chairman of the Board · since 2018
Vice President - Finance, Principal Financial Officer · since 2018
Chief Financial Officer · since 2019
Narinderjeet Singh
Senior Vice President - Pharmaceutical Sciences and Manufacturing · since 2018
Girish N Aakalu
Chief Business Officer · since 2018
Thomas Andrew Davis
Chief Medical Officer · since 2018
George R Siber
Director · since 2007
Independent Director · since 2018
Independent Director · since 2016
Independent Director · since 2015
Independent Director · since 2017
Legal address
C/O THE CORPORATION TRUST COMPANY
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
100 Acorn Park Drive
Cambridge, MA 02140
US
Cambridge, MA 02140
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||